Clinical Trial Update: Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study in healthy subjects comparing two exploratory insulin degludec formulations and two exploratory IDegAsp formulations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• IDegAsp (insulin degludec/insulin aspart)
• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED